# Safety of Two Doses of Avaxim® 80U Pediatric (Inactivated Hepatitis A Vaccine) in Toddlers, Children and Adolescents

> **NCT02011763** · PHASE4 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 355 (actual)

## Conditions studied

- Hepatitis A
- Hepatitis A Virus

## Interventions

- **BIOLOGICAL:** Avaxim 80U Pediatric: Inactivated Hepatitis A Virus

## Key facts

- **NCT ID:** NCT02011763
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2014-09
- **Final completion:** 2015-08
- **Target enrollment:** 355 (ACTUAL)
- **Last updated:** 2015-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02011763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02011763, "Safety of Two Doses of Avaxim® 80U Pediatric (Inactivated Hepatitis A Vaccine) in Toddlers, Children and Adolescents". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02011763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*